|
KMID : 1161420230260090605
|
|
Journal of Medicinal Food
2023 Volume.26 No. 9 p.605 ~ p.615
|
|
|
Review of Patents for Anticancer Agents Targeting Adenosine Monophosphate-Activated Protein Kinase
|
|
Choi Hyo-Kyoung
Park Soo-Hyun
Lee Jang-Ho
Hwang Jin-Taek
|
|
|
Abstract
|
|
|
|
Cancer, caused by abnormal and excessive cellular proliferation, can invade and destroy surrounding tissues and organs through the spreading of cancer cells. A general strategy for developing anticancer agents is to identify biomarkers that, if targeted, can produce a robust cytotoxic effect with minimal side effects. Cell-cycle regulators, checkpoint regulatory genes, and apoptosis-related genes are well-known biomarkers that inhibit cancer cell proliferation. Several compounds that target such biomarkers have been patented and more are being developed as novel therapies. Recent additions to this list include anticancer drugs that target signaling pathway proteins, such as 5′ adenosine monophosphate-activated protein kinase (AMPK), which plays a vital role in cancer and normal cell metabolism. Herein, we have reviewed recent patents related to AMPK-targeting anticancer drugs and discussed the mechanisms of action of these drugs. We conclude that these recently published patents include several attractive compounds and methods for targeting AMPK. Further research and clinical trials are required to elucidate the comprehensive role of AMPK in cancer cell metabolism, identify its associated signal transduction systems, and develop novel activators that may find applications in cancer therapy.
|
|
|
KEYWORD
|
|
|
AMPK, anticancer activity, bioactive compounds, chemotherapy, patents
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|